Results 31 to 40 of about 17,319 (251)

Determination of Mifepristone (RU-486) and Its Metabolites in Maternal Blood Sample after Pharmacological Abortion

open access: yesMolecules, 2022
The aim of the study was the development and validation of the UHPLC-QqQ-MS/MS method for the determination of mifepristone in human blood as well as the identification and quantification of its metabolites after self-induced pharmacological abortion ...
Paweł Szpot   +3 more
doaj   +1 more source

Mifepristone reduces insulin resistance in patient volunteers with adrenal incidentalomas that secrete low levels of cortisol : a pilot study [PDF]

open access: yes, 2013
Background: Incidental adrenal masses are commonly detected during imaging for other pathologies. 10% of the elderly population has an ‘adrenal incidentaloma’, up to 20% of these show low-grade autonomous cortisol secretion and 60% of patients with ...
Rita Chadarevian   +19 more
core   +1 more source

Mifepristone Treatment in Pregnant Murine Model Induced Mammary Gland Dysplasia and Postpartum Hypogalactia

open access: yesFrontiers in Cell and Developmental Biology, 2020
Mammary gland dysplasia and postpartum hypogalactia often occur in humans and in the livestock breeding industry. However, their underlying mechanisms are not clear yet.
Hongmei Zhu   +7 more
doaj   +1 more source

Comparative effectiveness, safety and acceptability of medical abortion at home and in a clinic: a systematic review. [PDF]

open access: yes, 2011
OBJECTIVE: To compare medical abortion practised at home and in clinics in terms of effectiveness, safety and acceptability. METHODS: A systematic search for randomized controlled trials and prospective cohort studies comparing home-based and clinic ...
Free, Caroline   +7 more
core   +1 more source

Optimized pharmacological control over the AAV-Gene-Switch vector for regulable gene therapy

open access: yesMolecular Therapy: Methods & Clinical Development, 2021
Gene therapy in its current design is an irreversible process. It cannot be stopped in case of unwanted side effects, nor can expression levels of therapeutics be adjusted to individual patient’s needs.
Shi Cheng   +4 more
doaj   +1 more source

Synergistic lethality of mifepristone and LY294002 in ovarian cancer cells [PDF]

open access: yes, 2013
We have previously shown that the antiprogestin and antiglucocorticoid mifepristone inhibits the growth of ovarian cancer cells. In this work, we hypothesized that cellular stress caused by mifepristone is limited to cytostasis and that cell killing is ...
Wempe, Stacy L.   +2 more
core   +1 more source

How did the introduction of mifepristone impact the availability of abortion care in Ottawa? A qualitative study with abortion patients

open access: yesFACETS, 2020
In 2017, mifepristone and misoprostol became available for early pregnancy termination as the combination pack Mifegymiso® in Ottawa, Ontario, Canada.
Kathryn J. LaRoche   +2 more
doaj   +1 more source

Advances in the management of uterine fibroids [PDF]

open access: yes, 2009
Uterine fibroids are extremely common, with major surgery the current main management option; uterine artery embolisation is an alternative, but risks to fertility are unclear.
Munro, Kirsty I, Critchley, Hilary Od
core   +1 more source

Mifepristone [PDF]

open access: yesCanadian Medical Association Journal, 2018
Sheila, Dunn, Melissa, Brooks
  +7 more sources

Post protocol residual thickness as a negative predictor for pharmacological treatment in early pregnancy loss. [PDF]

open access: yesInt J Gynaecol Obstet
Abstract Objective To determine the rate of pharmacological treatment failure in early pregnancy loss, assess post‐treatment residua thickness as a predictor of retained products of conception (RPOC), identify a clinically relevant cutoff, and evaluate additional clinical and sonographic predictors. Methods This retrospective cohort study was conducted
Pertez-Machluf R   +7 more
europepmc   +2 more sources

Home - About - Disclaimer - Privacy